<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35142699</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1673-5374</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neural regeneration research</Title>
          <ISOAbbreviation>Neural Regen Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>(D-Ser2) oxyntomodulin recovers hippocampal synaptic structure and theta rhythm in Alzheimer's disease transgenic mice.</ArticleTitle>
        <Pagination>
          <StartPage>2072</StartPage>
          <EndPage>2078</EndPage>
          <MedlinePgn>2072-2078</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.4103/1673-5374.335168</ELocationID>
        <Abstract>
          <AbstractText>In our previous studies, we have shown that (D-Ser2) oxyntomodulin (Oxm), a glucagon-like peptide 1 (GLP-1) receptor (GLP1R)/glucagon receptor (GCGR) dual agonist peptide, protects hippocampal neurons against Aβ<sub>1-42</sub>-induced cytotoxicity, and stabilizes the calcium homeostasis and mitochondrial membrane potential of hippocampal neurons. Additionally, we have demonstrated that (D-Ser2) Oxm improves cognitive decline and reduces the deposition of amyloid-beta in Alzheimer's disease model mice. However, the protective mechanism remains unclear. In this study, we showed that 2 weeks of intraperitoneal administration of (D-Ser2) Oxm ameliorated the working memory and fear memory impairments of 9-month-old 3×Tg Alzheimer's disease model mice. In addition, electrophysiological data recorded by a wireless multichannel neural recording system implanted in the hippocampal CA1 region showed that (D-Ser2) Oxm increased the power of the theta rhythm. In addition, (D-Ser2) Oxm treatment greatly increased the expression level of synaptic-associated proteins SYP and PSD-95 and increased the number of dendritic spines in 3×Tg Alzheimer's disease model mice. These findings suggest that (D-Ser2) Oxm improves the cognitive function of Alzheimer's disease transgenic mice by recovering hippocampal synaptic function and theta rhythm.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Guang-Zhao</ForeName>
            <Initials>GZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiovascular Medicine, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Qi-Chao</ForeName>
            <Initials>QC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Wei-Ran</ForeName>
            <Initials>WR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Hong-Yan</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Hui-Min</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jian-Ji</ForeName>
            <Initials>JJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Xin-Rui</ForeName>
            <Initials>XR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jia-Xin</ForeName>
            <Initials>JX</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Mei-Na</ForeName>
            <Initials>MN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Functional Laboratory Center, Shanxi Medical University, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hölscher</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Jin-Shun</ForeName>
            <Initials>JS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao-Jun</ForeName>
            <Initials>ZJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Shanxi Medical University; Key Laboratory of Cellular Physiology, Ministry of Education; Key Laboratory of Cellular Physiology in Shanxi Province, Taiyuan, Shanxi Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neural Regen Res</MedlineTA>
        <NlmUniqueID>101316351</NlmUniqueID>
        <ISSNLinking>1673-5374</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">(D-ser2) oxyntomodulin</Keyword>
        <Keyword MajorTopicYN="N">Alzheimer’s disease</Keyword>
        <Keyword MajorTopicYN="N">cognitive decline</Keyword>
        <Keyword MajorTopicYN="N">glucagon-like peptide-1</Keyword>
        <Keyword MajorTopicYN="N">hippocampus</Keyword>
        <Keyword MajorTopicYN="N">local field potential</Keyword>
        <Keyword MajorTopicYN="N">synapse</Keyword>
        <Keyword MajorTopicYN="N">theta rhythm</Keyword>
      </KeywordList>
      <CoiStatement>None</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35142699</ArticleId>
        <ArticleId IdType="pmc">PMC8848598</ArticleId>
        <ArticleId IdType="doi">10.4103/1673-5374.335168</ArticleId>
        <ArticleId IdType="pii">NeuralRegenRes_2022_17_9_2072_335168</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ansorge MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol. 2007;7:8–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17188022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C, Stoeckel LE, Holtzman DM, Nathan DM. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14:168–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6098968</ArticleId>
            <ArticleId IdType="pubmed">29377010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Today. 2016;21:802–818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26851597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5831666</ArticleId>
            <ArticleId IdType="pubmed">28781108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J, Rovira C. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J Neurosci. 2009;29:10144–10152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6664983</ArticleId>
            <ArticleId IdType="pubmed">19675248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17498508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basalay MV, Davidson SM, Yellon DM. Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality? Neural Regen Res. 2020;15:1852–1853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7513965</ArticleId>
            <ArticleId IdType="pubmed">32246632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borovac J, Bosch M, Okamoto K. Regulation of actin dynamics during structural plasticity of dendritic spines: Signaling messengers and actin-binding proteins. Mol Cell Neurosci. 2018;91:122–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30004015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bragin A, Jandó G, Nádasdy Z, Hetke J, Wise K, Buzsáki G. Gamma (40-100 Hz) oscillation in the hippocampus of the behaving rat. J Neurosci. 1995;15:47–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6578273</ArticleId>
            <ArticleId IdType="pubmed">7823151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai HY, Yang JT, Wang ZJ, Zhang J, Yang W, Wu MN, Qi JS. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease. Biochem Biophys Res Commun. 2018;495:1034–1040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29175324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai HY, Hölscher C, Yue XH, Zhang SX, Wang XH, Qiao F, Yang W, Qi JS. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats. Neuroscience. 2014;277:6–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24583037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cherrington AD. Glucagon Physiology. Can J Diabetes. 2010;34:187–188.</Citation>
        </Reference>
        <Reference>
          <Citation>Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015;4:718–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4588458</ArticleId>
            <ArticleId IdType="pubmed">26500843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017;27:101–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28558878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duffy AM, Hölscher C. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease. Neuroscience. 2013;228:294–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23103794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graham DL, Durai HH, Trammell TS, Noble BL, Mortlock DP, Galli A, Stanwood GD. A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain. J Comp Neurol. 2020;528:2445–2470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7392814</ArticleId>
            <ArticleId IdType="pubmed">32170734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grieco M, Giorgi A, Gentile MC, d’Erme M, Morano S, Maras B, Filardi T. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci. 2019;13:1112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6813233</ArticleId>
            <ArticleId IdType="pubmed">31680842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 2002;416:396–400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11919622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol. 2006;2:159–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16932542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89:481–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21312223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han WN, Hölscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging. 2013;34:576–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22592020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han YF, Holscher C, Wang ZJ, Zhang J, Yuan L, Tong JQ, Wang DD, Wu MN, Qi JS. Neuroprotective effects of a novel antidiabetic drug (D-Ser2)Oxm on amyloid β protein-induced cytotoxicity. Sheng Li Xue Bao. 2016;68:265–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27350199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey RJ, Morando L, Rasetti R, Strata P. Spontaneous electrical activity and dendritic spine size in mature cerebellar Purkinje cells. Eur J Neurosci. 2005;21:1777–1784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15869473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasselmo ME. What is the function of hippocampal theta rhythm? --Linking behavioral data to phasic properties of field potential and unit recording data. Hippocampus. 2005;15:936–949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16158423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hölscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs. 2020;29:333–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32175781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu MM, Yan XD, Zhang XM, Bai Y, Zhao F, Qi JS. Application of wireless neuronal recording system in fear conditioning of Alzheimer's disease mice - hippocampal Theta oscillation observation. Sheng Li Xue Bao. 2018;70:571–578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30377697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540:230–235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5656389</ArticleId>
            <ArticleId IdType="pubmed">27929004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Author Correction: Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2018;562:E1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30046102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19:687–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7032048</ArticleId>
            <ArticleId IdType="pubmed">30266970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474–481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14747300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao SS, Bu XL, Liu YH, Zhu C, Wang QH, Shen LL, Liu CH, Wang YR, Yao XQ, Wang YJ. Sex dimorphism profile of Alzheimer's disease-type pathologies in an APP/PS1 mouse model. Neurotox Res. 2016;29:256–266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26707129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Shimada Y, Fujiwara K, Ikeguchi T. Reproducing infra-slow oscillations with dopaminergic modulation. Sci Rep. 2017;7:2411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5445087</ArticleId>
            <ArticleId IdType="pubmed">28546544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraeuter AK, Guest PC, Sarnyai Z. The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol Biol. 2019;1916:105–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30535688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laws KR, Irvine K, Gale TM. Sex differences in cognitive impairment in Alzheimer's disease. World J Psychiatry. 2016;6:54–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4804268</ArticleId>
            <ArticleId IdType="pubmed">27014598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, Wherrett J, Naglie G, Hamani C, Smith GS, Lozano AM. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol. 2010;68:521–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20687206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev. 2007;56:384–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17920690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Liu K, Zhao J, Holscher C, Li GL, Liu YZ. Neuroprotective role of (Val(8)GLP-1-Glu-PAL in an in vitro model of Parkinson's disease. Neural Regen Res. 2016a;11:326–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4810999</ArticleId>
            <ArticleId IdType="pubmed">27073388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Jiao JJ, Su Q, Hölscher C, Zhang J, Yan XD, Zhao HM, Cai HY, Qi JS. A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca(2+) homeostasis in 3×Tg-AD mice. Neuropharmacology. 2020;170:108042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32147454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Jiao JJ, Hölscher C, Wu MN, Zhang J, Tong JQ, Dong XF, Qu XS, Cao Y, Cai HY, Su Q, Qi JS. A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3×Tg mouse model of Alzheimer's disease. Hippocampus. 2018;28:358–372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29473979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Feng Y, Wu W, Zhao J, Fu C, Li Y, Ding Y, Wu B, Gong Y, Yang G, Zhou X. Sex differences between APPswePS1dE9 mice in A-beta accumulation and pancreatic islet function during the development of Alzheimer's disease. Lab Anim. 2016b;50:275–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26519428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis. 2010;19:1205–1219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948479</ArticleId>
            <ArticleId IdType="pubmed">20308787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Zhang Y, Zheng X, Fang T, Yang X, Luo X, Guo A, Newell KA, Huang XF, Yu Y. Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflammation. 2018;15:112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5907415</ArticleId>
            <ArticleId IdType="pubmed">29669582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynch AM, Pathak N, Flatt YE, Gault VA, O’Harte FP, Irwin N, Flatt PR. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus. Eur J Pharmacol. 2014;743:69–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25246014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017;39:46–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5411330</ArticleId>
            <ArticleId IdType="pubmed">27810402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McHugh TJ, Blum KI, Tsien JZ, Tonegawa S, Wilson MA. Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice. Cell. 1996;87:1339–1349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8980239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal K, Katare DP. Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. Diabetes Metab Syndr. 2016;10:S144–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26907971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31:224–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18479783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nuzzo D, Picone P, Baldassano S, Caruana L, Messina E, Marino Gammazza A, Cappello F, Mulè F, Di Carlo M. Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. Curr Alzheimer Res. 2015;12:723–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26159189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12895417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, et al.  (2020) The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 18:e3000410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7360023</ArticleId>
            <ArticleId IdType="pubmed">32663219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol. 2012;215:335–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3493657</ArticleId>
            <ArticleId IdType="pubmed">23019069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25834231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5554542</ArticleId>
            <ArticleId IdType="pubmed">22930834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skaper SD, Facci L, Zusso M, Giusti P. Synaptic plasticity, dementia and Alzheimer disease. CNS Neurol Disord Drug Targets. 2017;16:220–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28088900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suresh J, Khor IW, Kaur P, Heng HL, Torta F, Dawe GS, Tai ES, Tolwinski NS. Shared signaling pathways in Alzheimer's and metabolic disease may point to new treatment approaches. FEBS J. 2021;288:3855–3873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32853472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122:1316–1338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3314463</ArticleId>
            <ArticleId IdType="pubmed">22476197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toricelli M, Pereira AAR, Souza Abrao G, Malerba HN, Maia J, Buck HS, Viel TA. Mechanisms of neuroplasticity and brain degeneration: strategies for protection during the aging process. Neural Regen Res. 2021;16:58–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7818866</ArticleId>
            <ArticleId IdType="pubmed">32788448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker JM, Harrison FE. Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer's disease: impacts on cognitive decline. Nutrients. 2015;7:7332–7357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4586536</ArticleId>
            <ArticleId IdType="pubmed">26340637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XH, Li L, Hölscher C, Pan YF, Chen XR, Qi JS. Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience. 2010;170:1239–1248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20727946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XH, Yang W, Hölscher C, Wang ZJ, Cai HY, Li QS, Qi JS. Val8-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats. J Neurosci Res. 2013;91:568–577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23335292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZJ, Han YF, Zhao F, Yang GZ, Yuan L, Cai HY, Yang JT, Holscher C, Qi JS, Wu MN. A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice. Horm Behav. 2020;118:104640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31765661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woon WL, Cichocki A, Vialatte F, Musha T. Techniques for early detection of Alzheimer's disease using spontaneous EEG recordings. Physiol Meas. 2007;28:335–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17395990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang JT, Wang ZJ, Cai HY, Yuan L, Hu MM, Wu MN, Qi JS. Sex differences in neuropathology and cognitive behavior in APP/PS1/tau triple-transgenic mouse model of Alzheimer's disease. Neurosci Bull. 2018a;34:736–746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6129237</ArticleId>
            <ArticleId IdType="pubmed">30099679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018b;554:317–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29446381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang LY, Jin QQ, Hölscher C, Li L. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regen Res. 2021;16:1660–1670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8323666</ArticleId>
            <ArticleId IdType="pubmed">33433498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, Liu CC, Lu W, Wang X, Chen K, Cherukuri Y, Jia L, Martens YA, Job L, Shue F, Nguyen TT, Younkin SG, Graff-Radford NR, Wszolek ZK, Brafman DA, Asmann YW, et al.  APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nat Commun. 2020;11:5540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7608683</ArticleId>
            <ArticleId IdType="pubmed">33139712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuo C, Tian H, Li G, Chen M, Jiang D, Lin X, Xu Y, Wang W. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: a protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Brain Behav. 2019;9:e01423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6851815</ArticleId>
            <ArticleId IdType="pubmed">31617335</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
